Clinical studies have reported higher circulating IL-6 in endometrial adenocarcinoma (e.g., median 79.0 pg/mL vs. 31.0 pg/mL in controls) and greater STAT3 expression in tumors compared with benign hyperplasia; however, these findings come predominantly from small, tissue-level or cross-sectional datasets with heterogeneous assays and limited longitudinal follow-up [3,4,37,42]. This evidence concerns the gene STAT3 and endometrium adenocarcinoma.